Delving into the Latest Updates on LepVax with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Leprosy

Inactive Indication-

Originator Organization

Infectious Disease Research Institute

Active Organization

Infectious Disease Research Institute

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

AbstractLeprosy, also known as Hansen’s disease, is an age‐old chronic granulomatous infection characterized by prominent cutaneous and neurologic findings. Long known to be caused by Mycobacterium leprae, a new etiologic species was identified and linked in 2008, Mycobacterium lepromatosis. The BCG vaccine with highly variable efficacy may soon be replaced by the first leprosy‐specific subunit vaccine LepVax, which has recently moved forward in human trials. Recent evidence supporting theories of zoonotic transmission from armadillos and the less‐discussed Eurasian red squirrels has emerged. Knowledge on genetic polymorphisms that may increase leprosy susceptibility, such as the newly uncovered mitochondrial ribosomal protein S5 (MRPS5) polymorphism in the Chinese population, has provided a fresh perspective and direction. Further, we will delineate the latest information on leprosy, including the possible effects of leprosy coinfection with COVID‐19, HIV, and HTLV‐1, and the shift to newer leprosy therapies and treatment regimens.

01 Feb 2020·VaccineQ3 · MEDICINE

A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA–SE) in healthy adults

Q3 · MEDICINE

Article

Author: Vergara, Julie ; Reed, Steven G ; Day, Tracey ; Sagawa, Zachary K ; Coler, Rhea N ; Rolf, Tom ; Frevol, Aude ; Casper, Corey ; Marie Beckmann, Anna ; Duthie, Malcolm S

Healthy United States-based adult volunteers with no history of travel to leprosy-endemic countries were enrolled for the first-in-human evaluation of LepVax (LEP-F1 + GLA-SE). In total 24 volunteers participated in an open-labelclinicaltrial, with 21 receiving three injections of LepVax consisting of either 2 µg or 10 µg recombinantpolyprotein LEP-F1 mixed with 5 µg of the GLA-SE adjuvant formulation. LepVax doses were provided by intramuscular injection on Days 0, 28, and 56, and safety was evaluated for one year following the final injection. LepVaxwas safe and well tolerated at both antigen doses. Immunological analyses indicated that similar LEP-F1-specific antibody and Th1 cytokine secretion (IFN-γ, IL-2, TNF) were induced by each of the antigen doses evaluated within LepVax. This clinicaltrialof the first definedvaccinecandidate for leprosy demonstrates that LepVax is safe and immunogenic in healthy subjects and supports its advancement to testing in leprosy-endemic regions.

npj VaccinesQ1 · MEDICINE

Author Correction: LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection

Q1 · MEDICINE

ArticleOA

Author: Pena, Maria T ; Truman, Richard W ; Makino, Masahiko ; Polydefkis, Michael ; Sharma, Rahul ; Reed, Steven G ; Ebenezer, Gigi J ; Gillis, Thomas P ; Duthie, Malcolm S ; Cunningham, Kelly ; Maeda, Yumi

A source of funding was mistakenly left out of the Acknowledgements. This research was also funded by NIAID/HRSA Interagency Agreement no. AAI15006-004-00000.

100 Deals associated with LepVax

Login to view more data